Responses
Regular and young investigator award abstracts
Clinical trials in progress
341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)
Compose a Response to This Article
Other responses
No responses have been published for this article.